[1] Gray SP, Cooper ME. Diabetic nephropathy in 2010: Alleviating
the burden of diabetic nephropathy [J]. Nat Rev
Nephrol, 2011,7(2):71-73.
[2] Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a
novel adipokine associated with obesity and metabolic syndrome
[J]. Endocrinology, 2007,148(10):4687-4694.
[3] Hu W, Yu Q, Zhang J, et al. Rosiglitazone ameliorates
diabetic nephropathy by reducing the expression of Chemerin
and ChemR23 in the kidney of streptozotocin- induced
diabetic rats [J]. Inflammation, 2012,35(4):1287-1293.
[4] Lan HY. Transforming growth factor- β/Smad signalling in
diabetic nephropathy [J]. Clin Exp Pharmacol Physiol,
2012,39(8):731-738.
[5] Roh SG, Song SH, Choi KC, et al. Chemerin-- a new
adipokine that modulates adipogenesis via its own receptor
[J]. Biochem Biophys Res Commun, 2007,362(4):1013-
1018.
[6] Hu W, Feng P. Elevated serum chemerin concentrations
are associated with renal dysfunction in type 2 diabetic patients
[J]. Diabetes Res Clin Pract, 2011,91(2):159-163.
[7] Shields J, Maxwell AP. Managing diabetic nephropathy
[J]. Clin Med, 2010,10(5):500-550.
[8] Lan HY. Transforming growth factor- β/Smad signalling in
diabetic nephropathy [J]. Clin Exp Pharmacol Physiol,
2012,39(8):731-738.